[Studies on cefoperazone concentration in human biliary tract and clinical effect for acute cholecystitis and cholangitis (author's transl)]. 1980

S Hirasawa, and H Abe, and E Bekki, and I Hashimoto, and Y Sawada, and T Nakamura, and J Mikami, and Y Watanabe

A new antibiotic drug of cephalosporin, with marked resistance to beta-lactamase, cefoperazone (CPZ) for parenteral use was used in 10 patients with acute cholecystitis or cholangitis with cholelithiasis. CPZ was given by drip intravenous injection at a daily dose of 1 to 4 g. Clinical response was excellent in 1 case, good in 7 cases, fair in 2 cases and poor was none. Clinical adverse effect was not recognized. And CPZ in a dose of 1 g was given intravenously during the operation to 6 of those patients. Tissue specimens of different sites were taken from removed organs. The materials of A-bile and B-bile were subsequently taken at intervals. Determination of CPZ concentration was performed according to paper disk method with Micrococcus luteus ATCC 9341 strain. CPZ concentrations in the A-bile increased quickly soon after injection, and reached high level peak at 30-min. to 1 hour, then they were very slow decline. CPZ was observed in the B-bile through the gallbladder wall, and reached high level concentration comparative quickly after intravenous injection. CPZ concentration in the gallbladder wall, was directly proportional to the degree of pathological changes of inflammation. On the CPZ concentration in patients with acute cholecystitis, the concentration in A-bile, B-bile and gallbladder wall were observed extremely higher than the MIC or CPZ for Escherichia coli. CPZ therefore will be a very useful drug when used for chemotherapy of biliary tract infection.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002438 Cefoperazone Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections. Cefobid,Cefoperazon,Cefoperazone Sodium,Cefoperazone Sodium Salt,Céfobis,T-1551,T1551,Salt, Cefoperazone Sodium,Sodium Salt, Cefoperazone,Sodium, Cefoperazone,T 1551
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D002761 Cholangitis Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both. Cholangitides
D002764 Cholecystitis Inflammation of the GALLBLADDER; generally caused by impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, or other diseases. Empyema, Gallbladder,Gallbladder Inflammation,Empyema, Gall Bladder,Gall Bladder Empyema,Gallbladder Empyema,Inflammation, Gallbladder
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute

Related Publications

S Hirasawa, and H Abe, and E Bekki, and I Hashimoto, and Y Sawada, and T Nakamura, and J Mikami, and Y Watanabe
May 1979, The Japanese journal of antibiotics,
S Hirasawa, and H Abe, and E Bekki, and I Hashimoto, and Y Sawada, and T Nakamura, and J Mikami, and Y Watanabe
September 1993, The Medical clinics of North America,
S Hirasawa, and H Abe, and E Bekki, and I Hashimoto, and Y Sawada, and T Nakamura, and J Mikami, and Y Watanabe
August 1980, The Japanese journal of antibiotics,
S Hirasawa, and H Abe, and E Bekki, and I Hashimoto, and Y Sawada, and T Nakamura, and J Mikami, and Y Watanabe
September 1979, The Japanese journal of antibiotics,
S Hirasawa, and H Abe, and E Bekki, and I Hashimoto, and Y Sawada, and T Nakamura, and J Mikami, and Y Watanabe
December 1980, The Japanese journal of antibiotics,
S Hirasawa, and H Abe, and E Bekki, and I Hashimoto, and Y Sawada, and T Nakamura, and J Mikami, and Y Watanabe
August 1980, The Japanese journal of antibiotics,
S Hirasawa, and H Abe, and E Bekki, and I Hashimoto, and Y Sawada, and T Nakamura, and J Mikami, and Y Watanabe
May 1979, The Japanese journal of antibiotics,
S Hirasawa, and H Abe, and E Bekki, and I Hashimoto, and Y Sawada, and T Nakamura, and J Mikami, and Y Watanabe
August 1980, The Japanese journal of antibiotics,
S Hirasawa, and H Abe, and E Bekki, and I Hashimoto, and Y Sawada, and T Nakamura, and J Mikami, and Y Watanabe
June 1981, The Japanese journal of antibiotics,
S Hirasawa, and H Abe, and E Bekki, and I Hashimoto, and Y Sawada, and T Nakamura, and J Mikami, and Y Watanabe
January 1981, The Japanese journal of antibiotics,
Copied contents to your clipboard!